Real Life Pharmacology - Pharmacology Education for Health Care Professionals

Tirzepatide (Mounjaro) Pharmacology Podcast

01.12.2023 - By Eric Christianson, PharmD; Pharmacology Expert and Clinical PharmacistPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

On this episode I discuss the pharmacology of tirzepatide. I'm appreciative of Derek Borkowski who operates Pyrls for providing a free PDF of the 2023 ADA Diabetes Guidelines when you subscribe for an account at Pyrls.com/rlp - Tirzepatide makes its first appearance in the diabetes guidelines for its ability to promote weight loss.

Tirzepatide is a combination GIP and GLP-1 agonist that is currently indicated for diabetes with reductions of A1C in the range of about 2 points.

Much like GLP-1 agonists, tirzepatide can cause GI upset and other gastrointestinal adverse effects like diarrhea.

Tirzepatide doesn't have a large number of drug interactions which is nice. Corticosteroids can counteract its blood sugar-lowering effects while sulfonylureas and insulin may significantly increase the risk for hypoglycemia.

More episodes from Real Life Pharmacology - Pharmacology Education for Health Care Professionals